Genzyme v. TKT Patent Appeal Is Second Front In Orphan Exclusivity Battle
An appeals court decision in the Genzyme v. Transkaryotic Therapies patent case could have implications for the marketing of the companies' Fabry disease products in the U.S. and Europe
You may also be interested in...
Transkaryotic Therapies is bringing back Michael Astrue to head a turnaround effort as the company looks to recover from a recent series of adverse regulatory and judicial decisions
Genzyme's Fabrazyme and Transkaryotic Therapies' Replagal will split the 5,000-patient Fabry's disease market in Europe following the awarding of co-exclusive orphan status by the European Commission.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011